Cancer Science · 2019 · 51 citations · 12 references
PharmacyPharmacokineticsPharmacologyCancer PharmacologyImmunotherapyOncology PharmacotherapyBiomarker ValidationHematologic Malignancy PharmacotherapyHematologic Malignancy TherapyPharmacokinetics Of Monoclonal AntibodiesToxicity ManagementTyrosine Kinase InhibitorsAdverse Drug EventsBruton Tyrosine KinaseBruton's Tyrosine Kinase InhibitorsPredictive BiomarkersRefractory Chronic Lymphocytic LeukemiaRelapsed Chronic Lymphocytic LeukemiaTyrosine Kinase Inhibitor PharmacokineticsTyrosine Kinase Inhibitor Therapy
We evaluated the safety, efficacy, pharmacokinetics, pharmacodynamics and predictive biomarkers of tirabrutinib, a second-generation, enhanced-selectivity Bruton's tyrosine kinase inhibitor in Japanese patients with relapsed/refractory B-cell non-Hodgkin lymphoma (B-cell NHL) and chronic lymphocytic leukemia (CLL). This was an open-label, multicenter, phase I study. Seventeen patients (male N = 8) with a median age of 70 years were enrolled in 4 dose cohorts (160 mg once daily [N = 3], 320 mg once daily [N = 3], 480 mg once daily [N = 4] and 300 mg twice daily [N = 7]); 4 patients had continued tirabrutinib administration as of 4 January 2018. The maximum tolerated dose was not reached. Pneumonitis (N = 1) was the dose-limiting toxicity for 300 mg twice daily. Common adverse events (AEs) were rash (35.3%) and vomiting (29.4%). Eight patients (47.1%) developed grade ≥3 AEs: neutropenia (23.5%), anemia (11.8%) and leukopenia (11.8%) were frequent. The overall response rate (≥PR) was 76.5% (13/17 patients), including 4 DLBCL patients with no CD79A/B or MYD88 mutations, and 1 CLL patient with a TP53 mutation, providing promising data for future developments. Of 16 patients with measurable lesions during the screening period, 12 showed ≥50% reductions in tumor diameter. In many patients, the tumor size decreased soon after beginning treatment. The maximum serum concentration for tirabrutinib was 611, 1220, 1280 and 886 ng/mL on Day 1 and 484, 971 1940, and 961 ng/mL on Day 28 for Cohorts 1-4, respectively. Tirabrutinib pharmacokinetics were linear, with little accumulation following multiple doses. Tirabrutinib was well tolerated and showed promising efficacy for B-cell NHL/CLL.
12
Michael Hallek, Bruce D. Cheson, Daniel Catovsky et al. · Blood · 2008 · 3.2K citations · Full text
Medicine, Hematology, Oncology +14
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
John C. Byrd, Richard R. Furman, Steven Coutré et al. · New England Journal of Medicine · 2013 · 2.2K citations · Full text
Medicine, Hematology, Oncology +12
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
Michael Wang, Simon Rule, Peter Martin et al. · New England Journal of Medicine · 2013 · 1.7K citations · Full text
Medicine, Hematology, Pharmacology +17
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
Wyndham H. Wilson, Ryan M. Young, Roland Schmitz et al. · Nature Medicine · 2015 · 1.1K citations · Full text